Biologics Outsourcing Global Market – Forecast to 2025

Publishing Date : August, 2017
Report Code : HCBT0112
Price:
Single license $7,200
Site license $9,000
Global license $12,000


The biologics outsourcing global market is expected to grow at double digit CAGR to reach $70.3 billion by 2025. Biologics are therapeutic entities composed of sugars, proteins, or nucleic acids made from natural sources such as human, animal or micro organisms. Biologics can also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (transplantation), cell therapies and gene therapies. Like small molecule drugs, these drugs are intended for treatment of diseases and medical conditions. However, Biologics bring into picture higher range of specificity in treating a disease condition as the biologic entities like monoclonal antibodies and recombinant proteins target specific areas in the molecular mechanism of disease action.

Although biologics are much costlier than small molecule drugs, these classes of drugs prove to be highly beneficial for the patient and also bring about 40% higher profit to the manufacturers when compared to small molecule drug treatments. Due to the increasing demand for biologics drugs and increased regulatory approvals for these drugs, there is huge demand for biologics manufacture and testing at various levels of clinical studies as well as commercial supply. The Large Biopharma companies are coming up with strategies to cut down on their operational costs and concentrate more on their core competencies by outsourcing this piece of work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These organizations bridge the gap between demand and supply and ensure the drug discovery process gets much faster and convenient thus bringing life saving drugs to the market to reach the needy patients.

The biologics outsourcing global market is estimated region wise with various drug discovery, development and manufacturing segments and their market shares. This section also included the market sizing of antibodies, recombinant proteins, vaccines, and others which included gene therapy, cell therapy. The emerging trends and strategies adopted by global biopharmaceutical companies and their impact on outsourcing market were discussed. A list of approved drugs (2012-2016) along with phase wise pipeline analysis for biologics was included.

  • In depth assessment of all segments and sub segments of Biologics Outsourcing global market
  • Regional analysis of biologics outsourcing global market
  • Market sizing based on type of Biologics, Therapeutic areas and end users
  • Emerging trends and strategies
  • A list of approved drugs (2012-2016) along with phase wise and modality based pipeline analysis for biologics
  • Market share analysis of major players in biologics outsourcing global market.
  • Biologics services cost analysis for various modalities
  • Service provider matrix based on service offerings, revenues and employee size
  • 1     BIOLOGICS OUTSOURCING GLOBAL MARKET
    • 1.1     INTRODUCTION
    • 1.2     LANDSCAPE OF BIOLOGICS MARKET
    • 1.3     BIOLOGICS GLOBAL MARKET
      • 1.3.1     NORTH AMERICA
      • 1.3.2     ASIA PACIFIC
    • 1.4     CHINA BIOLOGICS OUTSOURCING MARKET
    • 1.5     CHINA VS INDIA - BIOLOGICS MARKET
      • 1.5.1     REGULATIONS AND GOVERNMENT INITIATIVES
      • 1.5.2     CAPABILITIES AND TECHNOLOGIES
  • 2     MARKET ANALYSIS
    • 2.1     INTRODUCTION
    • 2.2     FACTORS INFLUENCING MARKET
      • 2.2.1     DRIVERS AND OPPORTUNITIES
        • 2.2.1.1     INCREASED INVESTMENT IN R&D BY PHARMACEUTICAL COMPANIES IS INCREASING THE OUTSOURCING
        • 2.2.1.2     ADOPTION OF BIOLOGICAL THERAPIES IN DISEASE MANAGEMENT
        • 2.2.1.3     SUCCESSFUL COLLABORATION AND LOW COST FOR OUTSOURCING
        • 2.2.1.4     INCREASING BIOLOGICS APPROVALS IN THE PAST YEAR
        • 2.2.1.5     INCREASING CHRONIC AND AUTOIMMUNE ILLNESSES
        • 2.2.1.6     INCREASING NUMBER OF BRANDED DRUGS GOING OFF-PATENT CREATES A SCOPE FOR BIOSIMILARS
        • 2.2.1.7     REQUIREMENT OF NOVEL BIOLOGICS THERAPEUTICS FOR CERTAIN DISEASES
        • 2.2.1.8     INCREASING DEMAND FOR ANTIBODY CONJUGATES AND BISPECIFIC ANTIBODIES
        • 2.2.1.9     ADVANCED TECHNOLOGIES FOR SCREENING, CELL LINE ENGINEERING AND BIOPROCESSING
        • 2.2.1.10     PHARMA COMPANIES RESTRICTING THEIR GLOBAL PRESENCE, REDUCING MANPOWER, LACK OF FACILITIES FOR DISCOVERY AND MANUFACTURING OF BIOLOGICS
      • 2.2.2     RESTRAINTS AND THREATS
        • 2.2.2.1     INTENSE COMPLEXITIES IN HANDLING BIOLOGICS
        • 2.2.2.2     REQUIREMENT OF HIGHLY SKILLED TECHNICIANS
        • 2.2.2.3     HIGH COST OF DRUG DEVELOPMENT PROCESS
        • 2.2.2.4     CHALLENGES IN ORAL FORMULATIONS WITH BIOLOGICS
        • 2.2.2.5     STRINGENT REGULATORY FRAMEWORKS
        • 2.2.2.6     HIGH CAPITAL AND TECHNICAL REQUIREMENTS TO OBTAIN GMP CERTIFICATIONS
        • 2.2.2.7     LIMITED IP PROTECTION IN DEVELOPING REGIONS
        • 2.2.2.8     HIGH CHANCES OF END STAGE FAILURE OF DRUG
        • 2.2.2.9     CONFLICT OF INTEREST BETWEEN PHARMACEUTICAL COMPANY AND CRO
  • 3     BIOLOGICS OUTSOURCING GLOBAL MARKET, MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     DISCOVERY AND PRE-CLINICAL DEVELOPMENT PROCESS
    • 3.3     BIOLOGICS OUTSOURCING GLOBAL MARKET, BY PRODUCT TYPE
      • 3.3.1     ANTIBODY
        • 3.3.1.1     MONOCLONAL ANTIBODY
        • 3.3.1.2     BISPECIFIC ANTIBODY
        • 3.3.1.3     ANTIBODY DRUG CONJUGATES
        • 3.3.1.4     OTHERS
      • 3.3.2     RECOMBINANT PROTEIN
      • 3.3.3     VACCINES
      • 3.3.4     OTHERS
        • 3.3.4.1     GENE THERAPY
        • 3.3.4.2     CELL THERAPY
        • 3.3.4.3     Others
    • 3.4     MARKET SHARE ANALYSIS
    • 3.5     COMPANY DEVELOPMENTS
      • 3.5.1     AGREEMENTS, PARTNERSHIPS & COLLABORATIONS
      • 3.5.2     ACQUISITIONS
      • 3.5.3     NEW SERVICE LAUNCH
      • 3.5.4     OTHER DEVELOPMENTS
    • 3.6     SERVICE COST ANALYSIS
      • 3.6.1     ANTIBODY PRODUCTION SERVICE COSTS
      • 3.6.2     CUSTOM MONOCLONAL ANTIBODY PRODUCTION SERVICE COSTS
      • 3.6.3     CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE COSTS
      • 3.6.4     PROTEIN PRODUCTION SERVICE COSTS
      • 3.6.5     ADDITIONAL ANTIBODY AND PROTEIN SERVICES
      • 3.6.6     GENE EDITTING SERVICES
      • 3.6.7     CAR-T/NK PLATFORM SERVICES
  • 4     BIOLOGICS OUTSOURCING GLOBAL MARKET – ANIMAL MODEL SERVICES
    • 4.1     INTRODUCTION
      • 4.1.1     COMPARISON MATRIX OF ANIMAL MODELS AND APPLICATIONS
      • 4.1.2     SMALL ANIMAL MODELS
      • 4.1.3     LARGE ANIMAL MODELS
    • 4.2     ETHICS AND REGULATIONS
    • 4.3     ALTERNATIVES TO ANIMAL MODELS
    • 4.4     OVERVIEW OF APPLICATIONS OF ANIMAL MODELS
    • 4.5     MARKET SHARE ANALYSIS
    • 4.6     COMPETITIVE LANDSCAPE
    • 4.7     COMPANY DEVELOPMENTS
  • 5     BIOLOGICS OUTSOURING GLOBAL MARKET - BIOMANUFACTURING
    • 5.1     INTRODUCTION
    • 5.2     CONTRACT BIOMANUFACTURING, BY PROCESS
      • 5.2.1     BIOMANUFACTURING BY MAMMALIAN CELL CULTURE
      • 5.2.2     BIOMANUFACTURING BY MICROBIAL CELL CULTURE
      • 5.2.3     BIOMANUFACTURING BY OTHER CELL CULTURE
    • 5.3     CONTRACT BIOMANUFACTURING GLOBAL MARKET, BY END USERS
      • 5.3.1     CONTRACT BIOMANUFACTURING OF DIAGNOSTICS
      • 5.3.2     CONTRACT BIOMANUFACTURING OF RESEARCH REAGENTS
      • 5.3.3     CONTRACT BIOMANUFACTURING OF THERAPEUTICS
    • 5.4     CONTRACT BIOMANUFACTURING GLOBAL MARKET, BY REGION
    • 5.5     COMPETITIVE LANDSCAPE
      • 5.5.1     CAPACITY COMPARISON
      • 5.5.2     CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY LEADING PLAYERS
    • 5.6     COMPANY DEVELOPMENTS
      • 5.6.1     MERGER AND ACQUISITION BY CMOS
      • 5.6.2     COLLABORATIONS
      • 5.6.3     CAPACITY EXPANSIONS
  • 6     BIOLOGICS OUTSOURCING GLOBAL MARKET - CELL LINE DEVELOPMENT
    • 6.1     INTRODUCTION
      • 6.1.1     MARKET DYNAMICS
    • 6.2     CELL LINE DEVELOPMENT
    • 6.3     HOST CELL LINES
    • 6.4     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM
      • 6.4.1     MICROBIAL EXPRESSION SYSTEMS
      • 6.4.2     MAMMALIAN EXPRESSION SYSTEM
      • 6.4.3     OTHERS
    • 6.5     CELL LINE DEVELOPMENT SERVICES, BY CELL TYPE
      • 6.5.1     CHO
      • 6.5.2     MURINE/MOUSE MYELOMA
      • 6.5.3     BABY HAMSTER KIDNEY (BHK) CELLS
      • 6.5.4     HYBRIDOMA
      • 6.5.5     HUMAN EMBRYONIC KIDNEY (HEK) CELLS
      • 6.5.6     HUMAN EMBRYONIC RETINAL CELLS (PER.C6)
      • 6.5.7     OTHERS
    • 6.6     CELL LINE DEVELOPMENT SERVICES, BY APPLICATIONS
      • 6.6.1     RESEARCH
      • 6.6.2     BIOPRODUCTION
      • 6.6.3     DIAGNOSTICS
    • 6.7     KEY DEVELOPMENTS
    • 6.8     MARKET SHARE ANALYSIS
  • 7     COMPANY PROFILES
    • 7.1     ABZENA PLC
      • 7.1.1     OVERVIEW
      • 7.1.2     FINANCIALS
      • 7.1.3     SERVICE PORTFOLIO
      • 7.1.4     KEY DEVELOPMENTS
      • 7.1.5     SWOT ANALYSIS
    • 7.2     ADIMAB LLC.
      • 7.2.1     OVERVIEW
      • 7.2.2     FINANCIALS
      • 7.2.3     SERVICE PORTFOLIO
      • 7.2.4     KEY DEVELOPMENTS
      • 7.2.5     SWOT ANALYSIS
    • 7.3     ALBANY MOLECULAR RESEARCH INC
      • 7.3.1     OVERVIEW
      • 7.3.2     FINANCIALS
      • 7.3.3     SERVICE PORTFOLIO
      • 7.3.4     KEY DEVELOPMENTS
      • 7.3.5     SWOT ANALYSIS
    • 7.4     BEIJING VITAL STAR BIOTECHNOLOGY CO. LTD.
      • 7.4.1     OVERVIEW
      • 7.4.2     FINANCIALS
      • 7.4.3     SERVICE PORTFOLIO
      • 7.4.4     KEY DEVELOPMENTS
      • 7.4.5     SWOT ANALYSIS
    • 7.5     BOEHRINGER INGELHEIM
      • 7.5.1     OVERVIEW
      • 7.5.2     FINANCIALS
      • 7.5.3     SERVICE PORTFOLIO
      • 7.5.4     KEY DEVELOPMENTS
      • 7.5.5     SWOT ANALYSIS
    • 7.6     CATALENT INC.
      • 7.6.1     OVERVIEW
      • 7.6.2     FINANCIALS
      • 7.6.3     SERVICE PORTFOLIO
      • 7.6.4     KEY DEVELOPMENTS
      • 7.6.5     SWOT ANALYSIS
    • 7.7     CHARLES RIVER LABORATORIES
      • 7.7.1     OVERVIEW
      • 7.7.2     FINANCIALS
      • 7.7.3     SERVICE PORTFOLIO
      • 7.7.4     KEY DEVELOPMENTS
      • 7.7.5     SWOT ANALYSIS
    • 7.8     CROWN BIOSCIENCES
      • 7.8.1     OVERVIEW
      • 7.8.2     FINANCIALS
      • 7.8.3     SERVICE PORTFOLIO
      • 7.8.4     KEY DEVELOPMENTS
      • 7.8.5     SWOT ANALYSIS
    • 7.9     GENOWAY
      • 7.9.1     OVERVIEW
      • 7.9.2     FINANCIALS
      • 7.9.3     SERVICE PORTFOLIO
      • 7.9.4     KEY DEVELOPMENTS
      • 7.9.5     SWOT ANALYSIS
    • 7.1     GENSCRIPT BIOTECH CORPORATION
      • 7.10.1     OVERVIEW
      • 7.10.2     FINANCIALS
      • 7.10.3     SERVICE PORTFOLIO
      • 7.10.4     KEY DEVELOPMENTS
      • 7.10.5     SWOT ANALYSIS
    • 7.11     GL BIOCHEM
      • 7.11.1     OVERVIEW
      • 7.11.2     FINANCIALS
      • 7.11.3     SERVICE PORTFOLIO
      • 7.11.4     KEY DEVELOPMENTS
      • 7.11.5     SWOT ANALYSIS
    • 7.12     HORIZON DISCOVERY GROUP, PLC
      • 7.12.1     OVERVIEW
      • 7.12.2     FINANCIALS
      • 7.12.3     SERVICE PORTFOLIO
      • 7.12.4     KEY DEVELOPMENTS
      • 7.12.5     SWOT ANALYSIS
    • 7.13     JACKSON LABORATORY
      • 7.13.1     OVERVIEW
      • 7.13.2     FINANCIALS
      • 7.13.3     SERVICE PORTFOLIO
      • 7.13.4     KEY DEVELOPMENTS
      • 7.13.5     SWOT ANALYSIS
    • 7.14     INNOVENT BIOLOGICS
      • 7.14.1     OVERVIEW
      • 7.14.2     FINANCIALS
      • 7.14.3     SERVICE PORTFOLIO
      • 7.14.4     KEY DEVELOPMENTS
      • 7.14.5     SWOT ANALYSIS
    • 7.15     JHL BIOTECH INC.
      • 7.15.1     OVERVIEW
      • 7.15.2     FINANCIALS
      • 7.15.3     SERVICE PORTFOLIO
      • 7.15.4     KEY DEVELOPMENTS
      • 7.15.5     SWOT ANALYSIS
    • 7.16     JOINN LABORATORIES CO. LTD
      • 7.16.1     OVERVIEW
      • 7.16.2     FINANCIALS
      • 7.16.3     SERVICE PORTFOLIO
      • 7.16.4     KEY DEVELOPMENTS
      • 7.16.5     SWOT ANALYSIS
    • 7.17     LONZA GROUP
      • 7.17.1     OVERVIEW
      • 7.17.2     FINANCIALS
      • 7.17.3     SERVICE PORTFOLIO
      • 7.17.4     KEY DEVELOPMENTS
      • 7.17.5     SWOT ANALYSIS
    • 7.18     MERCK KGAA
      • 7.18.1     OVERVIEW
      • 7.18.2     FINANCIALS
      • 7.18.3     PRODUCT PORTFOLIO
      • 7.18.4     KEY DEVELOPMENTS
      • 7.18.5     SWOT ANALYSIS
    • 7.19     PATHEON N.V.
      • 7.19.1     OVERVIEW
      • 7.19.2     FINANCIALS
      • 7.19.3     SERVICE PORTFOLIO
      • 7.19.4     KEY DEVELOPMENTS
      • 7.19.5     SWOT ANALYSIS
    • 7.2     PHARMALEGACY BIOTECHNOLOGY
      • 7.20.1     OVERVIEW
      • 7.20.2     FINANCIALS
      • 7.20.3     SERVICE PORTFOLIO
      • 7.20.4     KEY DEVELOPMENTS
      • 7.20.5     SWOT ANALYSIS
    • 7.21     PHARMARON
      • 7.21.1     OVERVIEW
      • 7.21.2     FINANCIALS
      • 7.21.3     SERVICE PORTFOLIO
      • 7.21.4     KEY DEVELOPMENTS
      • 7.21.5     SWOT ANALYSIS
    • 7.22     PROSCI INC.
      • 7.22.1     OVERVIEW
      • 7.22.2     FINANCIALS
      • 7.22.3     SERVICE PORTFOLIO
      • 7.22.4     KEY DEVELOPMENTS
      • 7.22.5     SWOT ANALYSIS
    • 7.23     PROTEOGENIX
      • 7.23.1     OVERVIEW
      • 7.23.2     FINANCIALS
      • 7.23.3     SERVICE PORTFOLIO
      • 7.23.4     KEY DEVELOPMENTS
      • 7.23.5     SWOT ANALYSIS
    • 7.24     PSYCHOGENICS INC
      • 7.24.1     OVERVIEW
      • 7.24.2     FINANCIALS
      • 7.24.3     SERVICE PORTFOLIO
      • 7.24.4     KEY DEVELOPMENTS
      • 7.24.5     SWOT ANALYSIS
    • 7.25     SELEXIS SA
      • 7.25.1     OVERVIEW
      • 7.25.2     FINANCIALS
      • 7.25.3     SERVICE PORTFOLIO
      • 7.25.4     KEY DEVELOPMENTS
      • 7.25.5     SWOT ANALYSIS
    • 7.26     SHANGHAI MEDICILON
      • 7.26.1     OVERVIEW
      • 7.26.2     FINANCIALS
      • 7.26.3     SERVICE PORTFOLIO
      • 7.26.4     KEY DEVELOPMENTS
      • 7.26.5     SWOT ANALYSIS
    • 7.27     SHANGPHARMA CORPORATION /SHANGHAI CHEMPARTNER
      • 7.27.1     OVERVIEW
      • 7.27.2     FINANCIALS
      • 7.27.3     SERVICE PORTFOLIO
      • 7.27.4     KEY DEVELOPMENTS
      • 7.27.5     SWOT ANALYSIS
    • 7.28     SINO BIOLOGICAL
      • 7.28.1     OVERVIEW
      • 7.28.2     FINANCIALS
      • 7.28.3     SERVICE PORTFOLIO
      • 7.28.4     KEY DEVELOPMENTS
      • 7.28.5     SWOT ANALYSIS
    • 7.29     SUNDIA MEDITECH CO., LTD.
      • 7.29.1     OVERVIEW
      • 7.29.2     FINANCIALS
      • 7.29.3     SERVICE PORTFOLIO
      • 7.29.4     KEY DEVELOPMENTS
      • 7.29.5     SWOT ANALYSIS
    • 7.3     SYNGENE INTERNATIONAL
      • 7.30.1     OVERVIEW
      • 7.30.2     FINANCIALS
      • 7.30.3     SERVICE PORTFOLIO
      • 7.30.4     KEY DEVELOPMENTS
      • 7.30.5     SWOT ANALYSIS
    • 7.31     TACONIC BIOSCIENCES
      • 7.31.1     OVERVIEW
      • 7.31.2     FINANCIALS
      • 7.31.3     SERVICE PORTFOLIO
      • 7.31.4     KEY DEVELOPMENTS
      • 7.31.5     SWOT ANALYSIS
    • 7.32     VIVA BIOTECH LTD.
      • 7.32.1     OVERVIEW
      • 7.32.2     FINANCIALS
      • 7.32.3     SERVICE PORTFOLIO
      • 7.32.4     KEY DEVELOPMENTS
      • 7.32.5     SWOT ANALYSIS
    • 7.33     WUXI APPTEC
      • 7.33.1     OVERVIEW
      • 7.33.2     FINANCIALS
      • 7.33.3     SERVICE PORTFOLIO
      • 7.33.4     KEY DEVELOPMENTS
      • 7.33.5     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     BIOSIMILAR PROJECTS IN CHINA
      • TABLE 2     HIGHLIGHTS OF THE REVISED GUIDELINES
      • TABLE 3     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY REGION (2015-2025) ($BN)
      • TABLE 4     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PRODUCT (2015-2025) ($BN)
      • TABLE 5     LIST OF BIOLOGICS APPROVED (2012-2016)
      • TABLE 6     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PHASE (2015-2025) ($BN)
      • TABLE 7     ANTIBODY OUTSOURCING GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2015-2025) ($BN)
      • TABLE 8     OTHERS GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2015-2025) ($BN)
      • TABLE 9     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY END USERS (2015-2025) ($BN)
      • TABLE 10     AGREEMENTS, PARTNERSHIP & COLLABOARTION (2016-2017)
      • TABLE 11     ACQUISITIONS (2016-2017)
      • TABLE 12     NEW SERVICE LAUNCH (2016-2017)
      • TABLE 13     OTHER DEVELOPMENTS (2016-2017)
      • TABLE 14     SERVICE COMPARISON MATRIX OF THE COMPANY BASED ON BIOLOGICS TYPE
      • TABLE 15     COMPARISON MATRIX OF ANIMAL MODELS AND APPLICATIONS
      • TABLE 16     MAJOR TYPES OF GENETICALLY ENGINEERED AND TRANSPLANTATION ANIMAL MODELS
      • TABLE 17     TYPICAL PRECLINICAL ISSUES OF BIOLOGICS
      • TABLE 18     ANIMAL MODEL SERVICE GLOBAL MARKET BY REGION ($MN)
      • TABLE 19     ANIMAL MODEL SERVICE GLOBAL MARKET BY TYPE OF ANIMAL SPECIES ($MN)
      • TABLE 20     ANIMAL MODEL SERVICE GLOBAL MARKET BY APPLICATION ($MN)
      • TABLE 21     ANIMAL MODEL SERVICE COST (DEVELOPMENT OF TRANSGENIC MOUSE)
      • TABLE 22     ANIMAL MODEL SERVICE COST (BASED ON DISEASE MODELS)
      • TABLE 23     ANIMAL MODEL SERVICE COST (IMAGING SERVICE COST BY AN ACADEMIC INSTITUTION)
      • TABLE 24     COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE THERAPEUTIC AREAS
      • TABLE 25     COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE IMMUNOLOGY/INFLAMMATION THERAPEUTIC AREAS
      • TABLE 26     COMPARISON MATRIX OF ANIMAL MODEL SERVICE COMPANIES AND MODELS IN RESPECTIVE FIBROSIS THERAPEUTIC AREAS
      • TABLE 27     COMPANY DEVELOPMENTS
      • TABLE 28     CAPACITY COMPARISON OF CONTRACT MANUFACTURING ORGANIZATIONS V’S IN-HOUSE CAPACITIES (L)
      • TABLE 29     CONTRACT MANUACTURING ORGANIZATIONS CAPACITY, BY PROCESS (L)
      • TABLE 30     ANTICANCER DRUGS SYNTHESIZED IN MICROBIAL CELL CULTURE
      • TABLE 31     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET BY END USERS ($BN)
      • TABLE 32     SECOND GENERATION PROTEIN THERAPEUTICS
      • TABLE 33     THERAPEUTIC VACCINES IN PIPELINE
      • TABLE 34     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET BY REGION ($BN)
      • TABLE 35     COMPANY COMPARISON MATRIX, BY MANUFACTURING CAPABILITY
      • TABLE 36     MERGERS AND ACQUITIONS (2015-2017)
      • TABLE 37     COLLABORATIONS (2016-2017)
      • TABLE 38     CAPACITY EXPANSIONS (2016-2017)
      • TABLE 39     CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, (2015-2025) ($MN)
      • TABLE 40     APPROVED BIOLOGICS AND CELL LINE TYPE (2012-2016)
      • TABLE 41     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2012-2016)
      • TABLE 42     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM, (2015-2025) ($MN)
      • TABLE 43     CELL LINE DEVELOPMENT SERVICES MARKET, BY CELL TYPE, (2015-2025) ($MN)
      • TABLE 44     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • TABLE 45     CELL LINE DEVELOPMENT SERVICES MARKET, BY APPLICATION, (2015-2025) ($MN)
      • TABLE 46     CELL LINE DEVELOPMENT TECHNOLOGIES
      • TABLE 47     CELL LINE DEVELOPMENT SERVICES COST
      • TABLE 48     KEY DEVELOPMENTS (2015-2017)
      • TABLE 49     COMPARISON MATRIX OF CELL LINE DEVELOPMENT PLAYERS AND SERVICES OFFERED
      • TABLE 50     ABZENA PLC: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 51     ABZENA PLC: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 52     ALBANY MOLECULAR RESEARCH INC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 53     ALBANY MOLECULAR RESEARCH INC: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 54     ALBANY MOLECULAR RESEARCH: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 55     BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 56     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 57     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 58     CATALENT INC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 59     CATALENT INC: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 60     CATALENT INC: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 61     CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 62     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 63     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 64     GENOWAY: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 65     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 66     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 67     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 68     HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 69     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 70     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 71     LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 72     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 73     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 74     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 75     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 76     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 77     PATHEON N.V.: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 78     PATHEON N.V.: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 79     SHANGHAI CHEMPARTNER: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 80     SYNGENE INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 81     SYNGENE INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 82     WUXI APPTEC: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)

      LIST OF FIGURES

      • FIGURE 1     TOP SELLING DRUGS AND APPROVALS, SMALL MOLECULES V’S BIOLOGICS, 2012-2016
      • FIGURE 2     TOP 30 BIOLOGICS PATENT EXPIRY, 2013-2038 AND RISE OF BIOSIMILARS
      • FIGURE 3     BIOLOGICS PIPELINE FROM PRECLINICAL TO REGISTRATION FOR EMERGING DISEASE AREAS
      • FIGURE 4     OUTLOOK OF BIOLOGICS GLOBAL MARKET (2015-2025)
      • FIGURE 5     OUTLOOK OF CHINA BIOLOGICS AND BIOLOGICS OUTSOURCING MARKET (2015-2025)
      • FIGURE 6     CHINA VS INDIA
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY REGION (2015-2025) ($BN)
      • FIGURE 9     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PRODUCT, (2016 V’S 2025) ($BN)
      • FIGURE 10     BIOLOGICS IN PIPELINE, BY TYPE (%)
      • FIGURE 11     DISCOVERY BIOLOGICS OUTSOURCING MARKET, BY SERVICES 2016 (%)
      • FIGURE 12     DISCOVERY BIOLOGICS OUTSOURCING MARKET, BY SERVICE TYPE, 2016 ($MN)
      • FIGURE 13     BIOLOGICS IN PIPELINE, BY PHASE (%)
      • FIGURE 14     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PHASE (2016 V’S 2025) ($BN)
      • FIGURE 15     ANTIBODY OUTSOURCING GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2016 V’S 2025) (%)
      • FIGURE 16     OTHERS GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2016 V’S 2025) ($BN)
      • FIGURE 17     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY END-USERS (2016 V’S 2025) ($BN)
      • FIGURE 18     BIOLOGICS OUTSOURCING GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016
      • FIGURE 19     RECENT DEALS IN BIOLOGICS OUTSOURCING
      • FIGURE 20     GENOME COMPARISON
      • FIGURE 21     DROT: ANIMAL MODELS
      • FIGURE 22     ANIMAL PROFILES
      • FIGURE 23     COMMON ANIMAL MODELS
      • FIGURE 24     ADVANTAGES AND DISADVANTAGES OF RODENT MODELS
      • FIGURE 25     ADVANTAGES AND DISADVANTAGES OF NHP
      • FIGURE 26     PRINCIPLES OF 3RS
      • FIGURE 27     PERCENTAGE OF ANIMALS USED IN DIFFRENT STAGES OF PHARMACUTICAL DEVELOPMENT
      • FIGURE 28     ANIMAL MODEL SERVICE GLOBAL MARKET, BY REGION ($MN)
      • FIGURE 29     ANIMAL MODEL SERVICE GLOBAL MARKET, BY TYPE OF ANIMAL SPECIES ($MN, %)
      • FIGURE 30     ANIMAL MODEL SERVICE GLOBAL MARKET, BY APPLICATION ($MN, %)
      • FIGURE 31     ANIMAL MODEL SERVICE OUTSOURCING GLOBAL MARKET SHARE (%)
      • FIGURE 32     COMPANY DEVELOPMENTS
      • FIGURE 33     MARKET DYNAMICS OF CONTRACT BIOMANUFACTURING GLOBAL MARKET
      • FIGURE 34     INDUSTRY PIPELINE FOR SMALL MOLECULE V’S BIOLOGICS
      • FIGURE 35     GLOBAL MANUFACTURING CAPACITY, CGMP V’S NON-CGMP, INHOUSE V’S CMO, 2016
      • FIGURE 36     CAPACITY UTILIZATION OF CONTRACT MANUFACTURING ORGANIZATIONS, BY STAGE (L)
      • FIGURE 37     CAPACITY COMPARISON OF MAMMALIAN, MICROBIAL AND OTHER CULTURE SYSTEMS (L)
      • FIGURE 38     BIO-MANUFACTURING OUTSOURCING GLOBAL MARKET, BY END USERS ($BN)
      • FIGURE 39     OUTLOOK OF BIOLOGICS CMO GLOBAL MARKET, BY REGION ($BN) AND PRODUCTION IN METRIC TONS, 2016
      • FIGURE 40     CAPACITY COMPOSITION OF TOP 10 CONTRACT MANUFACTURING ORGANIZATIONS (L)
      • FIGURE 41     MARKET SHARE ANALYSIS BY CONTRACT MANUFACTURING MAJOR PLAYERS, 2016
      • FIGURE 42     KEY DEALS (2016-2017)
      • FIGURE 43     MARKET DYNAMICS OF CELL LINE DEVELOPMENT
      • FIGURE 44     CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, (2016) ($MN)
      • FIGURE 45     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2012-2016)
      • FIGURE 46     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM, (2016 VS 2025) ($MN)
      • FIGURE 47     EXPRESSION SYSTEMS OF SOME APPROVED BIOLOGICS
      • FIGURE 48     CELL LINE DEVELOPMENT SERVICES MARKET, BY CELL TYPE, (2016 VS 2025) ($MN)
      • FIGURE 49     CELL LINE TYPE OF SOME APPROVED BIOLOGICS
      • FIGURE 50     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • FIGURE 51     CELL LINE DEVELOPMENT SERVICES MARKET, BY APPLICATION, (2016 VS 2025) ($MN)
      • FIGURE 52     KEY DEVELOPMENTS OF CELL LINE DEVELOPMENT MARKET PLAYERS, 2015-2017
      • FIGURE 53     MARKET SHARE ANALYSIS, BY CELL LINE DEVELOPMENT MAJOR PLAYERS (2016)
      • FIGURE 54     OVERVIEW: ABZENA PLC
      • FIGURE 55     SWOT: ABZENA PLC
      • FIGURE 56     SWOT: ADIMAB LLC
      • FIGURE 57     OVERVIEW: ALBANY MOLECULAR RESEARCH INSTITUTE
      • FIGURE 58     SWOT: ALBANY MOLECULAR RESEARCH, INC
      • FIGURE 59     SWOT: BEIJING VITAL STAR BIOTECHNOLOGY CO. LTD.
      • FIGURE 60     BOEHRINGER INGELHEIM REVENUE OVERVIEW
      • FIGURE 61     SWOT: BOEHRINGER INGELHEIM
      • FIGURE 62     OVERVIEW: CATALENT INC.
      • FIGURE 63     SWOT: CATALENT INC.
      • FIGURE 64     OVERVIEW: CHARLES RIVER LABORATORIES
      • FIGURE 65     SWOT: CHARLES RIVER LABORATORIES
      • FIGURE 66     SWOT: CROWN BIOSCIENCES
      • FIGURE 67     OVERVIEW: GENOWAY
      • FIGURE 68     SWOT: GENOWAY
      • FIGURE 69     OVERVIEW: GENSCRIPT BIOTECH CORPORATION
      • FIGURE 70     SWOT: GENSCRIPT BIOSCIENCES CORPORATION
      • FIGURE 71     SWOT: GL BIOCHEM
      • FIGURE 72     OVERVIEW: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 73     SWOT: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 74     SWOT: JACKSON LABORATORY
      • FIGURE 75     SWOT: INNOVENT BIOLOGICS
      • FIGURE 76     SWOT: JHL BIOTECH INC.
      • FIGURE 77     SWOT: JOINN LABORATORIES CO. LTD
      • FIGURE 78     OVERVIEW: LONZA GROUP
      • FIGURE 79     SWOT: LONZA GROUP
      • FIGURE 80     OVERVIEW: MERCK KGAA
      • FIGURE 81     SWOT: MERCK KGAA
      • FIGURE 82     OVERVIEW: PATHEON N.V.
      • FIGURE 83     SWOT: PATHEON N.V.
      • FIGURE 84     SWOT: PHARMALEGACY
      • FIGURE 85     SWOT: PHARMARON
      • FIGURE 86     SWOT: PROSCI. INC.
      • FIGURE 87     SWOT: PROTEOGENIX
      • FIGURE 88     SWOT: PSYCOGENICS INC
      • FIGURE 89     SWOT: SELEXIS SA
      • FIGURE 90     SWOT: SHANGHAI MEDICILON
      • FIGURE 91     SWOT: SHANGHAI CHEMPARTNER
      • FIGURE 92     SWOT: SINO BIOLOGICAL
      • FIGURE 93     SWOT: SUNDIA MEDITECH COMPANY LTD
      • FIGURE 94     SWOT: SYNGENE INTERNATIONAL
      • FIGURE 95     SWOT: TACONIC BIOSCIENCES
      • FIGURE 96     SWOT: VIVA BIOTECH LTD
      • FIGURE 97     SWOT: WUXI APPTEC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABBVIE
      • 2     ABEOMICS
      • 3     ABGENEX
      • 4     ABNOVA
      • 5     ABSOLUTE ANTIBODY
      • 6     ABVERIS ANTIBODY
      • 7     ABZENA
      • 8     ACCELOVANCE, INC.
      • 9     ACRO BIOSYSTEMS
      • 10     ADIMAB
      • 11     ADVINUS THERAPEUTICS LTD.
      • 12     AFFINITY LIFESCIENCES
      • 13     AGC ASAHI GLASS (CMC BIOLOGICS)
      • 14     ALEXION PHARMACEUTICALS
      • 15     AMERICAN PRECLINICAL SERVICES
      • 16     AMGEN
      • 17     AMPLIA PHARMATEK INC.
      • 18     AMPLYCELL (BELGIUM)
      • 19     AMRI INC
      • 20     ANOGEN
      • 21     ANTHEM BIOSCIENCES
      • 22     APPLIED BIOLOGICAL MATERIALS (ABMGOOD)
      • 23     APPLIED STEM CELL
      • 24     ARAGEN BIOSCIENCES (GVK BIOSCIENCES)
      • 25     ARTIMMUNE SAS
      • 26     ATCC
      • 27     ATHENA DISCOVERY, INC 
      • 28     ATUM
      • 29     AVANTGEN
      • 30     AVASTUS PRECLINICAL SERVICES
      • 31     AVID BIOSERVICES
      • 32     BEIJING VITALSTAR BIOTECHNOLOGY CO. LTD.
      • 33     BHARAT BIOTECH LTD
      • 34     BINEX CO. LTD.
      • 35     BIOAGILYTIX
      • 36     BIOCONNECT LIFE SCIENCES
      • 37     BIODEXTRIS
      • 38     BIOGEN
      • 39     BIOMEOSTASIS
      • 40     BIOMERE
      • 41     BIOMODELS LLC.
      • 42     BIOSPECTIVE INC.
      • 43     BOEHRINGER INGELHEIM
      • 44     BOLDER BIOPATH, INC.
      • 45     BPS BIOSCIENCE
      • 46     BTS RESEARCH
      • 47     BURLESON RESEARCH TECHNOLOGIES, INC.
      • 48     C & M BIOLABS
      • 49     CADILA HEALTHCARE LTD
      • 50     CARE RESEARCH, LLC
      • 51     CATALENT INC.
      • 52     CELLGENIX GMBH
      • 53     CELLOMICS TECHNOLOGY
      • 54     CELLTRION
      • 55     CELONIC
      • 56     CHARLES RIVER LABORATORIES
      • 57     CHEMPARTNER
      • 58     CHROMOS MOLECULAR SYSTEMS
      • 59     COBRA BIOLOGICS
      • 60     COOK PHARMICA
      • 61     COVANCE RESEARCH PRODUCTS
      • 62     CREATIVE ANIMODEL 
      • 63     CREATIVE BIOLABS
      • 64     CREATIVE BIOLABS
      • 65     CROWN BIOSCIENCE
      • 66     CRUCELL
      • 67     CURAXYS
      • 68     CYAGEN BIOSCIENCES INC
      • 69     CYTOVANCE BIOLOGICS
      • 70     DENDREON CORPORATION
      • 71     DIATHEVA
      • 72     ELABSCIENCE
      • 73     ENVIGO
      • 74     EPIMAB BIOTHERAPEUTICS
      • 75     EUROFINS
      • 76     EUROGENTEC
      • 77     EUROPA BIOPRODUCTS
      • 78     EVOTEC
      • 79     EXONBIO
      • 80     EXPLORA BIOLABS
      • 81     FAPON
      • 82     FUJIFILM DIOSYNTH BIOTECHNOLOGIES
      • 83     FUSION ANTIBODIES
      • 84     G&P BIOSCIENCES
      • 85     GATEWAY PHARMACOLOGY LABORATORIES
      • 86     GCC BIOTECH
      • 87     GE HEALTHCARE LIFE SCIENCES
      • 88     GEN TARGET
      • 89     GENOWAY
      • 90     GENSCRIPT
      • 91     GIGAGEN INC
      • 92     GLYCOTOPE GMBH
      • 93     GOODWINBIOTECHNOLOGY
      • 94     GTC BIOTHERAPEUTICS
      • 95     GTP TECHNOLOGY
      • 96     HERA BIOLABS
      • 97     HORIZON DISCOVERY
      • 98     IMMUNE TECHNOLOGY CORP.
      • 99     IMMUNOREAGENTS
      • 100     INFICURE BIO AB
      • 101     INNO BIOLOGICS
      • 102     INNOVA BIOSCIENCES
      • 103     INNOVENT BIO
      • 104     INTAS PHARMA
      • 105     INTESTINAL BIOTECH DEVELOPMENT 
      • 106     INTOUCH BIOSOLUTIONS LLC
      • 107     INTREXON
      • 108     INVITEK INC.
      • 109     INVIVOGEN
      • 110     IONTAS
      • 111     JACKSON LABORATORY
      • 112     JHL BIOTECH
      • 113     JSR CORPORATION (KBI BIOPHARMA)
      • 114     JUBILANT HOLLISTERSTIER
      • 115     KEMWELL BIOPHARMA
      • 116     LABCORP (COVANCE)
      • 117     LAKEPHARMA
      • 118     LAMPIRE BIOLOGICAL LABORATORIES
      • 119     LANCASTER UNIVERSITY
      • 120     LFB BIOMANUFACTURING
      • 121     LONZA
      • 122     LUINA BIO
      • 123     MABPLEX
      • 124     MAB-VENTURE
      • 125     MD BIOSCIENCES INC.
      • 126     MELIOR DISCOVERY INC.
      • 127     MENARINI BIOTECH S.R.L
      • 128     MERCK KGAA
      • 129     MILTENYI BIOTECH GMBH
      • 130     MORPHOTEK, INC., A SUBSIDIARY OF EISAI, INC
      • 131     MURIGENICS
      • 132     NEU ENCEPHARM GMBH
      • 133     NEUROSOLUTIONS LTD
      • 134     NOBLE LIFE SCIENCES
      • 135     NOVASEP
      • 136     NOVIMMUNE
      • 137     OAK BIOSCIENCES
      • 138     OMNIA BIOLOGICS
      • 139     OXFORD GENETICS
      • 140     PAIRIMMUNE
      • 141     PARAGON BIOSERVICES
      • 142     PATHEON
      • 143     PHARMACELSUS GMBH
      • 144     PHARMACEUTICAL PRODUCT DEVELOPMENT
      • 145     PHARMALEGACY LABORATORIES
      • 146     PHARMARON
      • 147     PHARMASEED
      • 148     PHYSIOGENEX
      • 149     POLYGENE TRANSGENETICS
      • 150     PRECISION ANTIBODY
      • 151     PREMAS BIOTECH PVT LTD
      • 152     PROBIOGEN
      • 153     PROFACGEN
      • 154     PROMAB
      • 155     PROTEOGENIX
      • 156     PROTEOS INC
      • 157     PURE BIOLOGICS
      • 158     RENOVO NEURAL, INC.
      • 159     RENTSCHLER BIOTECH GMBH
      • 160     SAMSUNG BIOLOGICS
      • 161     SANDOZ GMBH
      • 162     SARTORIUS STEDIM BIOTECH S.A.
      • 163     SBH SCIENCES, INC.
      • 164     SCIQUUS ONCOLOGY
      • 165     SCRIPPS LABORATORIES
      • 166     SELEXIS
      • 167     SERUM INSTITUTE OF INDIA
      • 168     SGI-DNA
      • 169     SGS
      • 170     SHANGHAI CHEMPARTNER
      • 171     SHANGHAI MEDICILON
      • 172     SINO BIOLOGICAL
      • 173     SMC LABORATORIES, INC.
      • 174     SOBRAN
      • 175     SPEED BIOSYSTEM
      • 176     SRI INTERNATIONAL
      • 177     SYD LABS
      • 178     SYNGENE
      • 179     SYRINX BIOANALYTICS
      • 180     TACONIC BIOSCIENCES
      • 181     TCG LIFESCIENCES
      • 182     TEXCELL
      • 183     THERAPURE BIOPHARMA
      • 184     TNO
      • 185     TOYOBO CO. LTD.
      • 186     TRANSCURE BIOSERVICES
      • 187     TRENZYME
      • 188     TRIBIOSCIENCES
      • 189     TRINITY BIOACTIVES LIMITED
      • 190     UGA BIOPHARMA
      • 191     U-PROTEIN EXPRESS BV
      • 192     VIFOR PHARMA LTD
      • 193     VIPRAGEN BIOSCIENCES PVT LTD.
      • 194     VIVA BIOTECH LTD
      • 195     VIVEBIOTECH S.L.
      • 196     WAISMAN CLINICAL BIOMANUFACTURING
      • 197     WILLIAM HARVEY RESEARCH LIMITED
      • 198     WOODLAND BIOSCIENCES
      • 199     WUXI APPTEC
      • 200     XCELLEREX
      • 201     YUMAB
      • 202     ZYMEWORKS INC.